118 related articles for article (PubMed ID: 36047997)
21. Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.
Stein EM
Future Oncol; 2018 Jan; 14(1):23-40. PubMed ID: 29243965
[TBL] [Abstract][Full Text] [Related]
22. Delineation of Molecular Lesions in Acute Myeloid Leukemia Patients at Diagnosis: Integrated Next Generation Sequencing and Cytogenomic Studies.
Papuc SM; Erbescu A; Cisleanu D; Ozunu D; Enache C; Dumitru I; Lupoaia Andrus E; Gaman M; Popov VM; Dobre M; Stanca O; Angelescu S; Berbec N; Colita A; Vladareanu AM; Bumbea H; Arghir A
Genes (Basel); 2021 May; 12(6):. PubMed ID: 34070898
[TBL] [Abstract][Full Text] [Related]
23. Genomic profiling and directed ex vivo drug analysis of an unclassifiable myelodysplastic/myeloproliferative neoplasm progressing into acute myeloid leukemia.
Hyrenius-Wittsten A; Sturesson H; Bidgoli M; Jonson T; Ehinger M; Lilljebjörn H; Scheding S; Andersson AK
Genes Chromosomes Cancer; 2016 Nov; 55(11):847-54. PubMed ID: 27240832
[TBL] [Abstract][Full Text] [Related]
24. MEGSA: A Powerful and Flexible Framework for Analyzing Mutual Exclusivity of Tumor Mutations.
Hua X; Hyland PL; Huang J; Song L; Zhu B; Caporaso NE; Landi MT; Chatterjee N; Shi J
Am J Hum Genet; 2016 Mar; 98(3):442-455. PubMed ID: 26899600
[TBL] [Abstract][Full Text] [Related]
25. Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation.
Kemps PG; Hebeda KM; Pals ST; Verdijk RM; Lam KH; Bruggink AH; de Lil HS; Ruiterkamp B; de Heer K; van Laar JA; Valk PJ; Mutsaers P; Levin MD; Hogendoorn PC; van Halteren AG
J Pathol Clin Res; 2021 Jan; 7(1):10-26. PubMed ID: 32852896
[TBL] [Abstract][Full Text] [Related]
26. Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity.
Kunimoto H; Meydan C; Nazir A; Whitfield J; Shank K; Rapaport F; Maher R; Pronier E; Meyer SC; Garrett-Bakelman FE; Tallman M; Melnick A; Levine RL; Shih AH
Cancer Cell; 2018 Jan; 33(1):44-59.e8. PubMed ID: 29275866
[TBL] [Abstract][Full Text] [Related]
27. Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia.
Huang X; Schwind S; Santhanam R; Eisfeld AK; Chiang CL; Lankenau M; Yu B; Hoellerbauer P; Jin Y; Tarighat SS; Khalife J; Walker A; Perrotti D; Bloomfield CD; Wang H; Lee RJ; Lee LJ; Marcucci G
Oncotarget; 2016 Sep; 7(37):59273-59286. PubMed ID: 27517749
[TBL] [Abstract][Full Text] [Related]
28. Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia.
Liang DC; Chen SH; Liu HC; Yang CP; Yeh TC; Jaing TH; Hung IJ; Hou JY; Lin TH; Lin CH; Shih LY
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28853218
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of allelic strength of human TET2 mutations and cooperation between Tet2 knockdown and oncogenic Nras mutation.
Chang YI; Damnernsawad A; Allen LK; Yang D; Ranheim EA; Young KH; Zhang J; Kong G; Wang J; Liu Y; Fu HY; Yang CS; Guo J; Song H; Zhang J
Br J Haematol; 2014 Aug; 166(3):461-5. PubMed ID: 24697267
[No Abstract] [Full Text] [Related]
30. Detection of
Anyanwu NCJ; Ella EE; Aminu M; Kazeem HM
J Immunoassay Immunochem; 2019; 40(6):605-616. PubMed ID: 31538838
[TBL] [Abstract][Full Text] [Related]
31. Mutations in chronic myelomonocytic leukemia and their prognostic relevance.
Jian J; Qiao Y; Li Y; Guo Y; Ma H; Liu B
Clin Transl Oncol; 2021 Sep; 23(9):1731-1742. PubMed ID: 33861431
[TBL] [Abstract][Full Text] [Related]
32. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
[TBL] [Abstract][Full Text] [Related]
33. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML.
Takahashi K; Jabbour E; Wang X; Luthra R; Bueso-Ramos C; Patel K; Pierce S; Yang H; Wei Y; Daver N; Faderl S; Ravandi F; Estrov Z; Cortes J; Kantarjian H; Garcia-Manero G
Leukemia; 2013 Oct; 27(10):2081-3. PubMed ID: 23774633
[No Abstract] [Full Text] [Related]
34. Early T-Cell Precursor Acute Lymphoblastic Leukemia in an Infant With an NRAS Q61R Mutation and Clinical Features of Juvenile Myelomonocytic Leukemia.
Raikar SS; Scarborough JD; Sabnis H; Bergsagel J; Wu D; Cooper TM; Keller FG; Wood BL; Bunting ST
Pediatr Blood Cancer; 2016 Sep; 63(9):1667-70. PubMed ID: 27145535
[TBL] [Abstract][Full Text] [Related]
35. Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent.
Leonard JT; Raess PW; Dunlap J; Hayes-Lattin B; Tyner JW; Traer E
J Hematol Oncol; 2016 Mar; 9():31. PubMed ID: 27036514
[TBL] [Abstract][Full Text] [Related]
36. An atypical chronic neutrophilic leukemia patient harboring ASXL1 and NRAS mutations associated with monoclonal plasma cell dyscrasia presenting as hemopericardium.
Han Q; Tao L; Jiang X; Chen H; Liu C; Sun M
Ann Hematol; 2021 Jan; 100(1):273-275. PubMed ID: 32052135
[No Abstract] [Full Text] [Related]
37. BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study.
Frank GA; Aleksakhina SN; Zavalishina LE; Kekeyeva TV; Venina AR; Ivantsov AO; Mitiushkina NV; Moiseyenko AV; Pfeifer W; Strelkova TN; Imyanitov EN
Melanoma Res; 2016 Oct; 26(5):442-7. PubMed ID: 27433783
[No Abstract] [Full Text] [Related]
38. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
Huang M; Yan C; Xiao J; Wang T; Ling R
Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
[TBL] [Abstract][Full Text] [Related]
39. KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival.
Vendramini E; Bomben R; Pozzo F; Benedetti D; Bittolo T; Rossi FM; Dal Bo M; Rabe KG; Pozzato G; Zaja F; Chiarenza A; Di Raimondo F; Braggio E; Parikh SA; Kay NE; Shanafelt TD; Del Poeta G; Gattei V; Zucchetto A
Leukemia; 2019 Aug; 33(8):2111-2115. PubMed ID: 30872781
[No Abstract] [Full Text] [Related]
40. Tobacco Smoke and Ras Mutations Among Latino and Non-Latino Children with Acute Lymphoblastic Leukemia.
Kaur M; de Smith AJ; Selvin S; Zhang L; Cunningham M; Kang MW; Hansen HM; Cooper RM; McKean-Cowdin R; Wiemels JL; Metayer C
Arch Med Res; 2016 Nov; 47(8):677-683. PubMed ID: 28476195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
